<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31001736</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1868-8500</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>2-3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hormones &amp; cancer</Title>
          <ISOAbbreviation>Horm Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.</ArticleTitle>
        <Pagination>
          <StartPage>120</StartPage>
          <EndPage>127</EndPage>
          <MedlinePgn>120-127</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12672-019-00363-4</ELocationID>
        <Abstract>
          <AbstractText>Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause ("PRE" group), while 14 after menopause ("POST" group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2-464.3 mIU/L) compared with those in long-term remission (94.3, 29.7-402.8 mIU/L; p &lt; 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p &lt; 0.005, OR 0.149, 95% CI 0.040-0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal's outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Indirli</LastName>
            <ForeName>Rita</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Padiglione Zonda, Via F. Sforza, 35, 20122, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrante</LastName>
            <ForeName>Emanuele</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Padiglione Zonda, Via F. Sforza, 35, 20122, Milan, Italy. emanuele.ferrante@policlinico.mi.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sala</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Padiglione Zonda, Via F. Sforza, 35, 20122, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giavoli</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Padiglione Zonda, Via F. Sforza, 35, 20122, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mantovani</LastName>
            <ForeName>Giovanna</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Padiglione Zonda, Via F. Sforza, 35, 20122, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arosio</LastName>
            <ForeName>Maura</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Padiglione Zonda, Via F. Sforza, 35, 20122, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>IG 2017-20594</GrantID>
            <Agency>Associazione Italiana per la Ricerca sul Cancro</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>Ricerca Corrente Fundus</GrantID>
            <Agency>Ministero della Salute</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>2015ZHKFTA - PRIN (Progetti di Ricerca di Interesse Nazionale)</GrantID>
            <Agency>Ministero dell'Istruzione, dell'Università e della Ricerca</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Horm Cancer</MedlineTA>
        <NlmUniqueID>101518427</NlmUniqueID>
        <ISSNLinking>1868-8497</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-62-4</RegistryNumber>
          <NameOfSubstance UI="D011388">Prolactin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000236" MajorTopicYN="N">Adenoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006966" MajorTopicYN="N">Hyperprolactinemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="Y">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017697" MajorTopicYN="Y">Premenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015175" MajorTopicYN="N">Prolactinoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">Dopamine agonist</Keyword>
        <Keyword MajorTopicYN="Y">Hyperprolactinemia</Keyword>
        <Keyword MajorTopicYN="Y">Menopause</Keyword>
        <Keyword MajorTopicYN="Y">Prolactinoma</Keyword>
        <Keyword MajorTopicYN="Y">Recurrence</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31001736</ArticleId>
        <ArticleId IdType="doi">10.1007/s12672-019-00363-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s12672-019-00363-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Swiss Med Wkly. 2006 Apr 15;136(15-16):254-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16708311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2012 Mar;15(1):25-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21409614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2017 Oct;20(5):578-584</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28710724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Endocrinol Invest. 2016 Dec;39(12):1377-1382</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27245604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrine. 2018 Jan;59(1):16-29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29177641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Endocrinol Metab. 2016 Feb;60(1):42-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26909481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrine. 2013 Dec;44(3):756-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23529671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrine. 2013 Aug;44(1):193-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23233277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2017 Aug;20(4):464-470</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28523537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19650784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2016 Dec;19(6):601-604</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27600151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2010 Apr;72(4):507-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19549247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2009 Jul;94(7):2428-36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19336508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2007 Sep;67(3):426-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17573902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2010 Oct;73(4):502-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrinol Metab Clin North Am. 2015 Mar;44(1):161-70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25732652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Endocrinol Invest. 1998 Dec;21(11):732-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9972671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Obstet Gynecol. 1977 Nov 1;129(5):557-64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">910845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2001 Mar;54(3):295-300</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11298080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrinol Metab Clin North Am. 1992 Dec;21(4):921-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1486882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bone. 2008 Mar;42(3):535-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18166509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuroendocrinology. 2013;98(4):299-310</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24355865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2016 Jun;19(3):303-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26830552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2015 Oct;18(5):745-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25500765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2003 Nov 20;349(21):2023-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14627787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell J. 2017 Oct;19(3):461-468</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28836408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aust N Z J Obstet Gynaecol. 2011 Aug;51(4):321-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21806583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrine. 2018 Jan;59(1):50-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29043560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2018 Sep;89(3):346-353</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29894000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 1998 Mar;83(3):761-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9506722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2011 Feb;96(2):273-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21296991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2005 Jul;63(1):26-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15963057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2011 Dec;14(4):299-306</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21301967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16886971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2007 Aug;92(8):2861-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17682084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2003 Sep;6(2):81-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14703017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Invest. 2002 Jan;109(2):277-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11805140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2013 Oct;79(4):537-44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23445298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2011 Dec;75(6):819-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21645021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Biochem. 2009 Jul 1;107(4):677-85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19365811</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
